DOCSLIB.ORG

2020 State of Nebraska Statutes Relating to Pharmacy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
2020 State of Nebraska Statutes Relating to Pharmacy 2020 STATE OF NEBRASKA STATUTES RELATING TO PHARMACY PRACTICE ACT Department of Health and Human Services Division of Public Health Licensure Unit 301 Centennial Mall South, Third Floor PO Box 94986 Lincoln, NE 68509-4986 STATUTE INDEX UNIFORM CONTROLLED SUBSTANCES ACT 28-401. Terms, defined. 28-401.01. Act, how cited. 28-401.02. Act; how construed. 28-402. Repealed. Laws 2001, LB 398, § 97. 28-403. Administering secret medicine; penalty. 28-404. Controlled substances; declaration. 28-405. Controlled substances; schedules; enumerated. 28-406. Registration; fees. 28-407. Registration required; exceptions. 28-408. Registration to manufacture or distribute controlled substances; factors considered. 28-409. Registrant; disciplinary action; grounds; procedure. 28-410. Records of registrants; inventory; violation; penalty; storage. 28-411. Controlled substances; records; by whom kept; contents; compound controlled substances; duties. 28-412. Narcotic drugs; administration to narcotic-dependent person; violation; penalty. 28-413. Distribution to another registrant; manner. 28-414. Controlled substance; Schedule II; prescription; contents. 28-414.01. Controlled substance; Schedule III, IV, or V; medical order, required; prescription; contents; pharmacist; authority to adapt prescription; duties. 28-414.02. Prescription created, signed, transmitted, and received electronically; records. 28-414.03. Controlled substances; maintenance of records; label. 28-414.04. Controlled substance; transfer. 28-414.05. Controlled substance; destruction; records. 28-414.06. Controlled substance; practitioner; provide information; limit on liability or penalty. 28-414.07. Controlled substances; chemical analysis; admissible as evidence in preliminary hearing. 28-415. Narcotic drugs; label; requirements. 28-416. Prohibited acts; violations; penalties. 28-417. Unlawful acts; violations; penalty. 28-418. Intentional violations; penalty. 28-419. Inhaling or drinking certain intoxicating substances; unlawful. 28-420. Selling or offering for sale certain compounds; use; knowledge of seller; unlawful. 28-421. Act, exceptions. 28-422. Selling or offering for sale certain compounds; register; maintain for one year. 28-423. Inducing or enticing; violation. 28-424. Violations; penalty. 28-425. Transferred to section 71-2510.01. 28-426. Repealed. Laws 1978, LB 748, § 61. 28-427. Additional penalties. 28-428. Controlled premises, defined; inspection; procedure. 28-429. Division of Drug Control; established; personnel; powers and duties; Nebraska State Patrol Drug Control and Education Cash Fund; created; use; investment; report; contents. 28-430. Department; enforce act; powers. 28-431. Seized without warrant; subject to forfeitures; disposition; manner; when; accepted as evidence; court costs and expenses; report to Auditor of Public Accounts; contents. 28-432. Complaint, pleading, or proceeding; burden of proof. 28-433. Appeal; procedure. 28-434. Education and research. 28-435. Licensee; reporting and investigation duties. 28-435.01. Health care facility; peer review organization or professional association; report required; contents; confidentiality; immunity; failure to report; civil penalty; disposition. 28-435.02. Insurer; duty to report violations. 28-435.03. Clerk of county or district court; report convictions and judgments; Attorney General or city or county prosecutor; provide information. 28-436. Repealed. Laws 1993, LB 627, § 26. 28-437. Uniformity of interpretation. i 28-438. Transferred to section 28-401.01. 28-439. Drug paraphernalia, defined; enumerated. 28-440. Drug paraphernalia; determination; factors considered. 28-441. Drug paraphernalia; use or possession; unlawful; penalty. 28-442. Drug paraphernalia; deliver or manufacture; unlawful; exception; penalty. 28-443. Delivery of drug paraphernalia to a minor; penalty. 28-444. Advertisement of drug paraphernalia; unlawful; penalty. 28-445. Imitation controlled substance; prohibited acts; determination; penalties; seizure. 28-446. Repealed. Laws 1992, LB 1019, § 130. 28-447. Repealed. Laws 1992, LB 1019, § 130. 28-448. Repealed. Laws 2009, LB 151, § 5. 28-449. Crystalline iodine; sale; requirements. 28-450. Ephedrine, pseudoephedrine, or phenylpropanolamine; immediate precursor; prohibited acts; violation; penalty. 28-451. Anhydrous ammonia; possession; penalty. 28-452. Ephedrine, pseudoephedrine, or phenylpropanolamine; possession; penalty. 28-453. Methamphetamine; retailer education program. 28-454. Repealed. Laws 2009, LB 151, § 5. 28-455. Methamphetamine Awareness and Education Fund; created; use; investment. 28-456. Phenylpropanolamine or pseudoephedrine; sold without a prescription; requirements; enforcement. 28-456.01. Pseudoephedrine or phenylpropanolamine; limitation on acquisition; violation; penalty. 28-458. Methamphetamine precursor; terms, defined. 28-459. Methamphetamine precursor; seller; duties; waiver authorized. 28-460. Methamphetamine precursor; access to exchange to law enforcement. 28-461. Methamphetamine precursor; seller; immunity. 28-462. Methamphetamine precursor; prohibited acts; penalty. 28-463. Cannabidiol; terms, defined; legislative findings. 28-464. Medical Cannabidiol Pilot Study; University of Nebraska and Nebraska Medicine; authority to produce or possess cannabidiol; patient; eligibility. 28-465. Medical Cannabidiol Pilot Study; created; physician or pharmacist; duties; risks and benefits form; use; participant; document; contents. 28-466. University of Nebraska Medical Center and Nebraska Medicine; duties; powers. 28-467. Prosecution for unlawful possession of marijuana; defense; restrictions on certain actions. 28-468. Report; contents. 28-469. Termination. 28-470. Naloxone; authorized activities; immunity from administrative action, criminal prosecution, or civil liability. 28-471. Lookalike substance; prohibited acts; penalty. 28-472. Drug overdose; exception from criminal liability; conditions. 28-473. Transferred to section 38-1,144. 28-474. Transferred to section 38-1,145. 28-475. Opiates; receipt; identification required. 28-476. Hemp; carry or transport; requirements; peace officer; powers; violation; penalty. CERTIFIED NURSE MIDWIFERY PRACTICE ACT (Nurse Midwife prescribing controlled substances) 38-611. Certified nurse midwife; authorized activities. Title 172 Chapter 104 Practice of Certified Nurse Midwives Regulations (104-005.01(6)) CERTIFIED REGISTERED NURSE ANESTHETIST PRACTICE ACT (Nurse Anesthetist administration of controlled substances) 38-706 Practice of anesthesia, defined; activities not subject to act. 38-711. Certified registered nurse anesthetist; performance of duties. ii MEDICINE AND SURGERY PRACTICE ACT (Physician Assistant prescribing of drugs and devices) 38-2055. Physician assistants; prescribe drugs and devices; restrictions. NURSE PRACTITIONER PRACTICE ACT (Nurse Practitioner prescribing controlled substances) 38-2315. Nurse practitioner; functions; scope. PHARMACY PRACTICE ACT 38-2801. Act, how cited. 38-2802. Definitions, where found. 38-2803. Accredited hospital or clinic, defined. 38-2804. Accredited pharmacy program, defined. 38-2805. Accredited school or college of pharmacy, defined. 38-2805.01 Accrediting body, defined. 38-2806. Administer, defined. 38-2807. Administration, defined. 38-2807.01. Bioequivalent, defined. 38-2807.02. Biological product, defined. 38-2807.03. Brand name, defined. 38-2808. Board, defined. 38-2808.01. Calculated expiration date, defined. 38-2809. Caregiver, defined. 38-2810. Chart order, defined. 38-2810.01. Chemically equivalent, defined. 38-2811. Compounding, defined. 38-2812. Delegated dispensing, defined. 38-2813. Deliver or delivery, defined. 38-2814. Device, defined. 38-2815. Dialysis drug or device distributor, defined. 38-2816. Dialysis drug or device distributor worker, defined. 38-2817. Dispense or dispensing, defined. 38-2818. Distribute, defined. 38-2818.01. Drug sample or sample medication; defined. 38-2818.02. Drug product, defined. 38-2818.03. Drug product select, defined. 38-2819. Drugs, medicines, and medicinal substances, defined. 38-2820. Electronic signature, defined. 38-2821. Electronic transmission, defined. 38-2821.01. Equivalent, defined. 38-2822. Facility, defined. 38-2823. Facsimile, defined. 38-2823.01. Generic name, defined. 38-2824. Graduate pharmacy education or approved program, defined. 38-2825. Hospital, defined. 38-2825.01. Hospital pharmacy, defined. 38-2825.02. Interchangeable biological product, defined. 38-2826. Labeling, defined. 38-2826.01 Long-term care facility, defined. 38-2826.02 Medical gas, defined. 38-2826.03 Medical gas device, defined. 38-2827. Repealed. Laws 2009, LB 604, § 12. 38-2828. Medical order, defined. 38-2829. Nonprescription drugs, defined. 38-2830. Patient counseling, defined. 38-2831. Pharmaceutical care, defined. iii 38-2832. Pharmacist, defined. 38-2833. Pharmacist in charge, defined. 38-2834. Pharmacist intern, defined. 38-2835. Pharmacy, defined. 38-2836. Pharmacy technician, defined. 38-2836.01. Practice agreement, defined. 38-2837. Practice of pharmacy, defined. 38-2838. Practitioner, defined. 38-2839. Prescribe, defined. 38-2840. Prescription, defined. 38-2841. Prescription drug or device or legend drug or device, defined. 38-2842. Public health clinic, defined. 38-2843. Public health clinic worker, defined. 38-2843.01. Repackage, defined. 38-2843.02. Remote dispensing, defined. 38-2843.03. Remote dispensing pharmacy, defined. 38-2843.04. Supervising pharmacy, defined. 38-2844. Signature, defined. 38-2845. Supervision, defined.
Load more

Recommended publications
  • Hospice and Assisted Living: Improving Care at the End of Life
    Hospice and Assisted Living: Improving Care at the End of Life Cherry Meier, RN, MSN eniors have embraced the concept of “aging in place.” S The challenge that inevitably occurs is the concept of “dying in place.” Seniors do not want to go through another change in living arrangements and do not want to become a burden on their families at the end of their life. Is it realistic to think that an eld- erly resident may be able to die in an assisted living (AL) residence? Depending upon what state you live in, it may or may not be possi- ble. Some states have very strict move-in and discharge require- ments that prohibit a dying resident from staying in their AL residence because they become bedbound, have a foley catheter, or require oxygen. Such requirements are usu- ally in response to concerns for life and safety in the event that a build- ing needs to be evacuated quickly or that the resident has complex 6 months or less if the illness runs equipment, and medical supplies needs that cannot be met by the AL its normal course and elects to re- related to the terminal illness. staff. Other states waive these rules ceive palliative/comfort care instead • On-call services, 24 hours a day. for residents who elect to receive of curative care. The AL residence • Bereavement care to the family/ care from hospice. is considered to be the resident’s loved ones following the death home, where the following services of the resident. The Medicare Hospice Benefit can be provided: The Medicare Hospice Benefit is • Services by an interdisciplinary The goal of care is to control the available to Medicare and Medicaid health care team comprised of resident’s pain and other uncomfort- beneficiaries in all states, except physicians, nurses, home health able symptoms through the dying Oklahoma, New Hampshire, and aides, social workers, chaplains, process.
    [Show full text]
  • Analgesic Effects and Pharmacologic Mechanisms of the Gelsemium
    www.nature.com/scientificreports OPEN Analgesic efects and pharmacologic mechanisms of the Gelsemium alkaloid koumine on a Received: 8 June 2017 Accepted: 13 October 2017 rat model of postoperative pain Published: xx xx xxxx Bo-Jun Xiong1, Ying Xu1,2, Gui-Lin Jin1,2, Ming Liu1, Jian Yang1,2 & Chang-Xi Yu1,2 Postoperative pain (POP) of various durations is a common complication of surgical procedures. POP is caused by nerve damage and infammatory responses that are difcult to treat. The neuroinfammation- glia-steroid network is known to be important in POP. It has been reported that the Gelsemium alkaloid koumine possesses analgesic, anti-infammatory and neurosteroid modulating activities. This study was undertaken to test the analgesic efects of koumine against POP and explore the underlying pharmacologic mechanisms. Our results showed that microglia and astroglia were activated in the spinal dorsal horn post-incision, along with an increase of proinfammatory cytokines (interleukin 1β, interleukin 6, and tumor necrosis factor α). Both subcutaneous and intrathecal (i.t.) koumine treatment after incision signifcantly prevented mechanical allodynia and thermal hyperalgesia, inhibited microglial and astroglial activation, and suppressed expression of proinfammatory cytokines. Moreover, the analgesic efects of koumine were antagonized by i.t. administration of translocator protein (18 kDa) (TSPO) antagonist PK11195 and GABAA receptor antagonist bicuculline. Together, koumine prevented mechanical allodynia and thermal hyperalgesia caused by POP. The pharmacologic mechanism of koumine-mediated analgesia might involve inhibition of spinal neuroinfammation and activation of TSPO. These data suggested that koumine might be a potential pharmacotherapy for the management of POP. Postoperative pain (POP) of varying duration is extremely common afer surgery.
    [Show full text]
  • Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances 2017
    INTERNATIONAL NARCOTICS CONTROL BOARD Precursors and chemicals frequently used in the illicit manufacture of narcotic drugs and psychotropic substances 2017 EMBARGO Observe release date: Not to be published or broadcast before Thursday, 1 March 2018, at 1100 hours (CET) UNITED NATIONS CAUTION Reports published by the International Narcotics Control Board in 2017 The Report of the International Narcotics Control Board for 2017 (E/INCB/2017/1) is supplemented by the following reports: Narcotic Drugs: Estimated World Requirements for 2018—Statistics for 2016 (E/INCB/2017/2) Psychotropic Substances: Statistics for 2016—Assessments of Annual Medical and Scientific Requirements for Substances in Schedules II, III and IV of the Convention on Psychotropic Substances of 1971 (E/INCB/2017/3) Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances: Report of the International Narcotics Control Board for 2017 on the Implementation of Article 12 of the United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 (E/INCB/2017/4) The updated lists of substances under international control, comprising narcotic drugs, psychotropic substances and substances frequently used in the illicit manufacture of narcotic drugs and psychotropic substances, are contained in the latest editions of the annexes to the statistical forms (“Yellow List”, “Green List” and “Red List”), which are also issued by the Board. Contacting the International Narcotics Control Board The secretariat of the Board may be reached at the following address: Vienna International Centre Room E-1339 P.O. Box 500 1400 Vienna Austria In addition, the following may be used to contact the secretariat: Telephone: (+43-1) 26060 Fax: (+43-1) 26060-5867 or 26060-5868 Email: [email protected] The text of the present report is also available on the website of the Board (www.incb.org).
    [Show full text]
  • Simvastatin Attenuates Renal Ischemia/Reperfusion Injury from Oxidative Stress Via Targeting Nrf2/HO‑1 Pathway
    4460 EXPERIMENTAL AND THERAPEUTIC MEDICINE 14: 4460-4466, 2017 Simvastatin attenuates renal ischemia/reperfusion injury from oxidative stress via targeting Nrf2/HO‑1 pathway YU ZHANG1, SHU RONG2, YI FENG1, LIQUN ZHAO1, JIANG HONG1, RUILAN WANG1 and WEIJIE YUAN2 Departments of 1Emergency Intensive Medicine and 2Nephrology, Shanghai General Hospital of Nanjing Medical University, Shanghai 200082, P.R. China Received August 31, 2016; Accepted June 15, 2017 DOI: 10.3892/etm.2017.5023 Abstract. Ischemia-reperfusion (I/R) injury of the kidneys pathway to ultimately protect the kidneys from I/R-associated is commonly encountered in the clinic. The present study oxidative damage. assessed the efficacy of simvastatin in preventing I/R‑induced renal injury in a rat model and investigated the corresponding Introduction molecular mechanisms. Rats were divided into 3 groups, including a sham, I/R and I/R + simvastatin group. The Ischemia/reperfusion (I/R) injury of the kidneys represents a results revealed that in the I/R group, the levels of blood urea challenge in the clinic and is commonly encountered in renal nitrogen, serum creatinine and lactate dehydrogenase were transplantation, hemorrhagic shock, partial nephrectomy and significantly higher than those in the sham group, which accidental or iatrogenic trauma, brining about serious injury was significantly inhibited by simvastatin pre‑treatment. to multiple organs, including renal tubules, brain and heart (1). I/R significantly decreased superoxide dismutase activity Therefore, it is urgent to find effective therapies and elucidate compared with that in the sham group, which was largely molecular mechanisms by which renal I/R injury may be rescued by simvastatin.
    [Show full text]
  • Self-Care for the Hospice Professional by Sally Hill Jones, Phd, LCSW
    A Delicate Balance: Self-Care For the Hospice Professional By Sally Hill Jones, PhD, LCSW Cindy, an experienced hospice professional, approached me one Monday morning, saying, “I think I’m losing it. Just the thought of seeing my patients today is too much.” She then described taking repeated showers but feeling that she still had the “smell of death” on her afterward. There had been an unusual number of deaths during her weekend on call, and as she named her patients, she began to cry. We devised a plan to begin her emotional processing that included taking the day off, journaling, talking to others she trusts, and saying good-bye to her patients. Service to individuals at the end of life and their families is an experience rich with meaning. Some important tasks can be accomplished only at life’s end, providing the opportunity for life review, healing, and coming to terms with one’s legacy. It is a time of potentially profound emotions and spiritual connections, letting go of the physical self and embracing the intangible inheritance left behind. To be involved professionally at this crucial time is deeply rewarding and yet demanding. Hospice staff regularly experience a wide range of powerful emotions, the mystical space between the physical and spiritual worlds, and the reality of loss and death. End-of-life experiences range from inspiring, graceful processes to difficult, complex situations with layers of long-standing problems, few resources, and the potential for abuse or suicide. Given the scope and intensity of hospice work, thoughtful, intentional focus on self-care is necessary for hospice professionals to remain effective.
    [Show full text]
  • High Throughput Determination of Multiple Toxic Alkaloids in Food By
    Application Note Food Testing & Agriculture High-Throughput Determination of Multiple Toxic Alkaloids in Food by UHPLC/MS/MS Authors Abstract Guoyin Lai, Lijian Wu, Zhongda Lin, Liyi Lin, Dunming Xu, This Application Note presents a simple sample preparation procedure followed Zhigang Zhang with an Agilent 1290 Infinity II LC combined with an Agilent 6470A triple quadrupole Technigue Center, LC/MS for simultaneous, high-throughput determination of multiple alkaloids in food Xiamen Customs, matrices. The matrix-matched calibration shows very good linear relationships for Xiamen, China the 18 alkaloids in the concentration range of 0.5 to 50 µg/L in the diluted, extracted matrices of bread, milk, wine, and rice powder. This corresponds to 5.0 to 500 µg/kg Meiling Lu in the matrices when considering the dilution factor of 10. The linear regression Agilent Technologies (China) coefficients for all the analytes are higher than 0.99. The signal-to-noise ratios Co., Ltd. (S/Ns) for all analytes are higher than 10 at the lowest calibration level of 0.5 µg/L, corresponding to 5.0 µg/kg in the samples. The recoveries for the analytes in four different matrices at 5, 50, and 250 µg/kg levels ranged from 90 to 110%, and the corresponding relative standard deviations were within 2.3 to 7.9%. The results demonstrated that the developed method has the advantages of high sensitivity, accuracy, and precision. The simple sample preparation combined with rapid LC/MS/MS detection allows high-throughput screening of alkaloid residues in food matrices. Introduction Experimental (pH 3). The tube was vortexed thoroughly for two minutes, then centrifuged Alkaloids are naturally occurring alkaline Standards and sample at 7,500 rpm for five minutes.
    [Show full text]
  • The Power of TRU COMPLIANCETM
    The Power of TRU COMPLIANCETM Compliant. Actionable. Ethical. THE The Gold Standard of GOLD Medication Reviews STANDARD CoPs-Compliant Med Reviews. Complete evaluation of medication history. EPCS Certified for controlled substances. Detailed clinical insights with actionable recommendations. Reduces lost and unfilled prescriptions. Less risk of adverse drug Drug Utilization Review shows cost-effective interactions and reactions. $ alternatives, recommends discontinuation of non-palliative medications. Fewer prescribing and dispensing errors. Covered vs. Non-covered medications: We provide industry-best practices for hospice and palliative medication coverage. CMS Reporting Recommendations on drug effectiveness, side effect CR-8358 and 10573 imported into your risks vs. drug benefits, interactions, duplicate EMR via SFTP. therapies, and drug therapy concurrently associated with laboratory monitoring. Opioid laxative report. Adverse Drug Reaction Reports. HCPCS coding. Alerts for inappropriate coverage The 5 Rights to a by Medicare Part D. Medication Pass The Best = Outcome The Right For the At the With the Right In the Right Drug Right Patient Right Time Route of Dosage Form Administration Introducing: Tru360TM Tru Partnership. Tru Customization. Tru Service.TM Tru360 is the most comprehensive, hospice-centered, patient-focused solution in the market today. Tru360 drives sustained cost reduction while improving patient satisfaction and outcomes. Tru360 is built on five key components that produce excellent end-of-life care in a cost-effective manner. PARTNERSHIP EFFICIENCY Real Collaboration. Powered by People. Intuitive Workflow. Proactive Intervention. Driven by Data. Real Results. We build a custom service model to fit your Our technology provides proactive intervention, workflow and your culture. Your Tru360 Team, streamlines pharmacy interaction and saves up including a dedicated pharmacist and account to $2,000 per nurse annually.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • The Effects of the Morphine Analogue Levorphanol on Leukocytes: Metabolic Effects at Rest and During Phagocytosis
    The effects of the morphine analogue levorphanol on leukocytes: Metabolic effects at rest and during phagocytosis Nancy Wurster, … , Penelope Pettis, Sharon Lebow J Clin Invest. 1971;50(5):1091-1099. https://doi.org/10.1172/JCI106580. Studies on bacteria have suggested that morphine-like drugs have effects on the cell membrane. To determine the effect of this class of drugs on a mammalian cell, we selected the rabbit peritoneal exudate granulocyte, which undergoes striking membrane changes during phagocytosis. We examined the effect in vitro of the morphine analogue, levorphanol on phagocytosis and metabolism by granulocytes incubated with and without polystyrene particles or live Escherichia coli. Levorphanol (1 or 2 mmoles/liter) decreased: (a) acylation of lysolecithin or lysophosphatidylethanolamine in the medium (which is stimulated about two-fold during phagocytosis) both at rest (40%) and during phagocytosis (60%); (b) uptake of latex particles and Escherichia coli, as judged by electron microscopy; (c) killing of live Escherichia coli (10-fold); (d) 14 14 + CO2 production from glucose-1- C during phagocytosis by at least 80%; (e) K content of granulocytes (35%); (f) oxidation of linoleate-1-14C by 50%, and its incorporation into triglyceride by more than 80%. However, levorphanol stimulated 2 to 3-fold the incorporation of linoleate-1-14C or palmitate-1-14C into several phospholipids. Glucose uptake, lactate production, and adenosine triphosphate (ATP) content are not affected by the drug. Thus, levorphanol does not appear to exert its effects through generalized metabolic suppression. Removal of levorphanol by twice resuspending the granulocytes completely reverses all inhibition. In line with observations on bacteria, it appears that the complex effects of levorphanol on […] Find the latest version: https://jci.me/106580/pdf The Effects of the Morphine Analogue Levorphanol on Leukocytes METABOLIC EFFECTS AT REST AND DURING PHAGOCYTOSIS NANcY WuRsTE, PETER ELSBACH, ERIc J.
    [Show full text]
  • Pharmacist's Role in Palliative and Hospice Care
    456 Medication Therapy and Patient Care: Specific Practice Areas–Guidelines ASHP Guidelines on the Pharmacist’s Role in Palliative and Hospice Care Palliative care arose from the modern hospice movement and and in advanced clinical practice (medication therapy man- has evolved significantly over the past 50 years.1 Numerous agement services, pain and symptom management consulta- definitions exist to describe palliative care, all of which fo- tions, and interdisciplinary team participation). cus on aggressively addressing suffering. The World Health Organization and the U.S. Department of Health and Human Purpose Services both stipulate the tenets of palliative care to include a patient-centered and family-centered approach to care, In 2002, ASHP published the ASHP Statement on the with the goal of maximizing quality of life while minimiz- Pharmacist’s Role in Hospice and Palliative Care.28 These 2 ing suffering. In its clinical practice guidelines, the National guidelines extend beyond the scope of that statement and Consensus Project for Quality Palliative Care of the National are intended to define the role of the pharmacist engaged in Quality Forum (NQF) describes palliative care as “patient the practice of PHC. Role definition will include goals for and family-centered care that optimizes quality of life by an- providing services that establish general principles and best ticipating, preventing, and treating suffering . throughout practices in the care of this patient population. This docu- the continuum of illness . addressing the
    [Show full text]
  • Hospice Employees' Perceptions of Their Work Environment
    International Journal of Environmental Research and Public Health Article Hospice Employees’ Perceptions of Their Work Environment: A Focus Group Perspective Rebecca H. Lehto 1,* , Carrie Heeter 2, Jeffrey Forman 3, Tait Shanafelt 4, Arif Kamal 5, Patrick Miller 6 and Michael Paletta 6 1 College of Nursing, Michigan State University, East Lansing, MI 48824, USA 2 Department of Media and Information, Communication Arts & Sciences, Michigan State University, East Lansing, MI 48824; [email protected] 3 Former Medical Director of Development, Karmanos Cancer Institute, Detroit, MI 48201, USA; jeff[email protected] 4 Department of Medicine, Stanford University, Stanford, CA 94304, USA; [email protected] 5 Department of Medicine, Duke Cancer Institute, Duke University, Durham, NC 27710, USA; [email protected] 6 Hospice of Michigan, 2366 Oak Valley Drive, Ann Arbor, MI 48103, USA; [email protected] (P.M.); [email protected] (M.P.) * Correspondence: [email protected] Received: 30 June 2020; Accepted: 17 August 2020; Published: 24 August 2020 Abstract: Burnout in healthcare professionals can lead to adverse effects on physical and mental health, lower quality of care, and workforce shortages as employees leave the profession. Hospice professionals are thought to be at particularly high risk for burnout. The purpose of the study was to evaluate workplace perceptions of interdisciplinary hospice care workers who provide care to patients at end of life. Six focus groups and one semi-structured interview were conducted with mixed group of social workers, managers, nurses, hospice aides, chaplains, support staff, and a physician (n = 19). Findings from the groups depicted both rewards and challenges of hospice caregiving.
    [Show full text]
  • Comparative Analysis of Gelsemine and Gelsemium Sempervirens Activity on Neurosteroid Allopregnanolone Formation in the Spinal Cord and Limbic System
    Hindawi Publishing Corporation Evidence-Based Complementary and Alternative Medicine Volume 2011, Article ID 407617, 10 pages doi:10.1093/ecam/nep083 Original Article Comparative Analysis of Gelsemine and Gelsemium sempervirens Activity on Neurosteroid Allopregnanolone Formation in the Spinal Cord and Limbic System Christine Venard,1 Naoual Boujedaini,2 Ayikoe Guy Mensah-Nyagan,1 and Christine Patte-Mensah1 1 Equipe “St´ero¨ıdes, Neuromodulateurs et Neuropathologies”, EA-4438 Universit´edeStrasbourg,Bˆatiment 3 de la Facult´edeM´edecine, F-67000 Strasbourg, France 2 Laboratoires BOIRON, Sainte-Foy-l`es-Lyon, France Correspondence should be addressed to Ayikoe Guy Mensah-Nyagan, [email protected] Received 10 February 2009; Accepted 15 June 2009 Copyright © 2011 Christine Venard et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Centesimal dilutions (5, 9 and 15 cH) of Gelsemium sempervirens are claimed to be capable of exerting anxiolytic and analgesic effects. However, basic results supporting this assertion are rare, and the mechanism of action of G. sempervirens is completely unknown. To clarify the point, we performed a comparative analysis of the effects of dilutions 5, 9 and 15 cH of G. sempervirens or gelsemine (the major active principle of G. sempervirens) on allopregnanolone (3α,5α-THP)productionintheratlimbicsystem (hippocampus and amygdala or H-A) and spinal cord (SC). Indeed, H-A and SC are two pivotal structures controlling, respectively, anxiety and pain that are also modulated by the neurosteroid 3α,5α-THP. At the dilution 5 cH, both G.
    [Show full text]